TD Cowen lowered the firm’s price target on BioNTech to $130 from $145 and keeps a Market Perform rating on the shares. The analyst noted its Covid vaccine sales beat estimates but its Comirnaty guidance was light. Also, its oncology pipeline progressing but slower than expected.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BNTX: